Sökning: "tumor immunotherapy"
Visar resultat 21 - 25 av 153 avhandlingar innehållade orden tumor immunotherapy.
21. Immunological aspects of intratumoral chemotherapy and immunotherapy in malignant brain tumors
Sammanfattning : Advances in surgery, chemo- and radiotherapy have only modestly improved survival rates of malignant brain tumor patients during the last decades. Emerging evidence suggests that an efficient treatment of malignant brain tumors will likely require the management of multiple aspects of tumor pathobiology in order to manipulate features as tumor heterogeneity and tumor immunosuppression. LÄS MER
22. Interaction studies of idiotypic and antiidiotypic antibodies at experimental tumor targeting
Sammanfattning : An increasing number of antibodies are being labeled with radionuclides for immunotargeting, but the negative side effects generated on normal tissues by the nuclide remains a significant problem. The clearing of non-tumor-targeted radiolabeled antibodies from the circulation contributes significantly to improved targeting; it has been demonstrated that anti-idiotypic antibodies can be used for this purpose. LÄS MER
23. Synergistic effects of mesenchymal stromal cells and immunotherapy in experimental brain tumors
Sammanfattning : Glioblastoma multiforme (GBM) is the most common and aggressive form of primary brain tumor. In spite of surgical resection, combined radiation therapy and chemotherapy, the mean survival is less than 15 months following diagnosis. LÄS MER
24. Translational and clinical aspects of pancreatic cancer
Sammanfattning : Pancreatic cancer is a disease with dismal prognosis due to late detection and ineffective treatments. The majority of the patients already have disseminated disease at the time of diagnosis. The only potential curative treatment, surgery, is extensive with high morbidity and non-ignorable mortality. LÄS MER
25. Experimental models of pediatric brain tumors. Establishment, immunophenotyping and clinical implications
Sammanfattning : Brain tumors are the most common solid tumors in children. Current treatment protocols fail in 25% of patients and are associated with significant long-term adverse effects in survivors. LÄS MER